Step therapy is one of the most widely used utilization management tools in employer-sponsored pharmacy benefits, and its impact on employer costs extends beyond the prescription drug line item. It requires plan members to try clinically appropriate, lower-cost first-line medications before the plan covers a more expensive alternative. Most employer-sponsored plans include step therapy in their formularies, and the evidence shows it reliably cuts drug spending in most therapy classes. A poorly designed program can still frustrate members and erode trust, which is why the exception process and the contract terms matter as much as the clinical logic.
Direct Cost Savings Through Pharmacy Spend Reduction
The most immediate and measurable effect of step therapy is a reduction in the average wholesale price (AWP) of the prescriptions dispensed. By steering utilization toward generic, biosimilar, or cost-effective brand medications as first-line therapy, employers reduce the per-claim cost of medications in high-spend therapeutic categories. The categories where step therapy is applied most often include:
- Specialty drugs for autoimmune conditions, such as requiring methotrexate before a biologic and preferring a biosimilar over the originator when one is available.
- Diabetes medications, such as requiring metformin before GLP-1 agonists.
- Mental health medications, such as requiring generic SSRIs before branded SNRIs.
Pharmacy benefit managers (PBMs) negotiate deeper discounts and rebates on preferred first-line agents, but how much of that value reaches the plan depends on contract terms. The size of the savings also varies by therapy class and by how tightly the current formulary is managed. A critical review of the empirical literature found consistent, statistically significant drug-cost reductions across classes, with the exception of antipsychotics. In one 20,000-member employer plan, step therapy reduced drug costs by $0.83 per member per month while the comparison group's costs rose, and a separate program targeting blood pressure medications cut drug costs by 13 percent. These reductions also lower the plan's exposure to new-to-market drugs with limited long-term safety data, avoiding spending on medications that are no more effective than existing, less expensive alternatives.
Potential for Cost Shifting and Indirect Expense
While the pharmacy budget often declines, a rigid protocol can erode those gains. The evidence on cost shifting is mixed. Five empirical studies have examined step therapy's effect on hospitalization and emergency costs, and none found statistically significant increases, though one reported higher outpatient expenditures. Other analyses show that step therapy can delay treatment access and shift costs toward other health care services, and individual cases of harm are documented. One involved an ulcerative colitis patient required to fail several drugs over six months before the insurer approved the prescribed treatment. When patients who fail or cannot tolerate first-line therapy wait too long for an effective drug, the risks include:
- Disease progression during the wait. A rheumatoid arthritis patient kept on a non-biologic that is not controlling the disease can develop progressive joint damage.
- Higher administrative and outpatient spending as physicians work the step process and manage flare-ups.
- Lost productivity and short-term disability claims from prolonged pain or uncontrolled symptoms.
Employers should evaluate total cost of care rather than the pharmacy silo alone. How large any medical offset becomes depends on how rigid the protocol is and how fast the exception process runs, so the strongest designs pair step therapy with clinical review and rapid prior authorization turnaround to prevent medically necessary delays.
Member Experience and Non-Adherence Risks
Step therapy can also affect medication adherence. When employees face multiple failed steps, cumbersome paperwork, or confusion about the process, some may abandon therapy. Non-adherence to blood pressure or cholesterol medication raises the risk of heart attack and stroke years later, and the employer eventually bears the cost of those events. The direct evidence on how much step therapy itself causes non-adherence is mixed, so the friction of the process matters as much as the protocol.
A frustrating step therapy experience also damages the perceived value of the benefits package. In a competitive labor market, a health plan that feels restrictive or burdensome can weigh on employee retention and recruitment, adding soft costs that are harder to quantify but equally real. Plan sponsors can blunt this by investing in clear communication, digital tools that guide members through the steps, and ombudsman services through their PBM or consultant that help members handle exception requests quickly.
Compliance and Fiduciary Considerations Under ERISA
For self-funded employer plans governed by the Employee Retirement Income Security Act (ERISA), step therapy programs must be built to meet fiduciary obligations. Plan fiduciaries must ensure the program is designed solely in the interest of participants and beneficiaries and does not create a discriminatory barrier to medically necessary care. Federal activity has raised the stakes for this oversight. The Safe Step Act, reintroduced in the 119th Congress as H.R. 5509 and S. 2903, would require ERISA group health plans to offer a clear, prompt exception process with determinations within 72 hours. The Consolidated Appropriations Act, 2026 adds rebate pass-through and data-reporting requirements for PBMs serving employer plans, and a Department of Labor proposed rule published January 30, 2026 would require PBMs to disclose compensation to self-funded plan fiduciaries and permit audits. Employers who fail to monitor their PBM's step therapy protocols may face legal risk and associated costs. A governance process that includes regular review of step therapy metrics and member appeals data protects the plan on both fronts, keeping the savings without harming covered individuals.
Maximizing Savings While Preserving Health Outcomes
To get the most from step therapy as a cost-management tool, leading employers are moving beyond simple, blanket fail-first mandates toward precision step therapy that accounts for:
- Genetic and biomarker-based criteria - Using lab results or prior treatment history to exempt members who are unlikely to respond to the first-line agent and reduce trial-and-error costs.
- Integrated medical and pharmacy data - Triggering steps only when the patient's diagnosis and comorbidity profile match the evidence. For instance, a plan might bypass step therapy for a diabetic with established cardiovascular disease and allow immediate use of an SGLT2 inhibitor with proven cardio-protective benefits.
- Rapid exception pathways - Guaranteeing a defined response window, such as 24 hours for urgent requests and 72 hours for routine ones, often through an electronic prior authorization portal that integrates with the electronic health record.
- Member-centric incentives - Offering reduced copays for completing step therapy successfully or participating in disease management coaching alongside the protocol, which improves adherence and long-term health, further lowering total costs.
When employers monitor performance through a balanced scorecard that tracks net cost per member per month, medical cost trend, disability days, and member satisfaction, step therapy moves from a blanket mandate to a managed program that controls drug spend without driving members away.
Rebate Steering and the Employer's Share of Savings
Step therapy saves money only if the savings flow to the plan. Manufacturer rebates are the hidden variable. Drugmakers pay PBMs for favorable formulary placement, which can mean keeping a product off the step list or steering steps toward a first-line drug that carries a larger rebate rather than the lowest net cost. The Federal Trade Commission's second interim staff report on pharmacy benefit managers, issued in January 2025, documented how rebates and fees can pull formulary choices toward the PBM's financial interests rather than the plan's. The Consolidated Appropriations Act, 2026 shifts part of this terrain by requiring PBMs to pass through 100 percent of rebates to employer health plans. For an employer, the practical step is to ask for net-cost comparisons and confirm the rebate pass-through in writing before crediting a step therapy program with savings.
The Bottom Line
Step therapy reliably reduces employer drug spend in most therapy classes in the short term, but its impact on total cost of care depends on program design, clinical oversight, and the employee experience. Plans that treat step therapy as a blunt cost-cutting tool risk member dissatisfaction and avoidable health deterioration that can erase pharmacy savings. Plans that invest in evidence-based, flexible, and well-communicated protocols, with a fast exception process and transparent contract terms, capture the savings without the backlash.
This article is for general information only and is not legal, tax, or medical advice. Employers should consult their own advisors.